You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
THIS SBIR PHASE I CONTRACT IS FOR A WEARABLE ALCOHOL BIOSENSOR THAT QUANTIFIES BAC IN REAL TIME.
SBC: DeLeon, Augustina S Topic: NIAAATechnology validation study of a wearable NIR spectrometer to quantify BAC in real time
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Electrochemical aptasensor for Anti-Tuberculosis antibiotic quantification
SBC: GUILD ASSOCIATES INC Topic: NIAIDSpecific AimsIn Phase I of this SBIRwe will complete three specific aimssynthesize stable combination adjuvant formulations that are compatible with an HVLP antigenidentify the combination adjuvant properties that augment the safe and durable immunity to Handdemonstrate the superior protective benefit of the new combination adjuvant over existing adjuvant solutions for pandemic influenza vaccinesI ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 396- IMAGING FOR CANCER IMMUNOTHERAPIES-MOONSHOT
SBC: COLUMBUS NANOWORKS, INC. Topic: NCIIn vivo imaging of cells labeled with fluorescent nanodiamondsFNDsis a new way of monitoring immune cells during cancer immunotherapyFNDs are non toxicinfinitely photostable nanomaterials that are easily conjugated with antibodiesand emit fluorescence in the near infrared spectral regionIn this Phase I SBIRwe will use a murine melanoma model and outline a plan to use FNDs for imaging immunosupress ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Advancing ARP-1536, an Anti-VE-PTP Antibody, as an Adjunctive Therapy for the Treatment of Sight-Threatening Retinopathies
SBC: Aerpio Therapeutics LLC Topic: NEIAbstract Diabetic macular edemaDMEis the leading cause of vision loss in the working age population whichconsidering the worldwide epidemic of diabetesrepresents a growing socioeconomic challengeDME is characterized by the destabilization of retinal blood vessels resulting in the accumulation of fluid in the maculathe area of the retina responsible for central visionThe current standard of care fo ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Well-Flushed Hydrodynamic Bearing for Miniature Blood Pumps
SBC: Perfusion Solutions, Inc. Topic: NHLBIVentricular assist devicesVAD sclearly have a role in cardiac medicinehow to precisely define that role is still subject to research and debateconsidering the possibilities of destination therapybridge to transplantbridge to recoverybridge to definitive therapy and possibly other variants one might specifyCertain VAD features are emerging as requiredadequate output to truly make a difference to th ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Software for OCT Analysis of Vascular Stents
SBC: DYAD MEDICAL, INC. Topic: NHLBIProject Summary. Dyad Medical, Inc. will create intravascular Optical Coherence Tomography (IVOCT) software for clinical, live time determination of stent apposition and for offline analysis of stent implantation. Every year, 100s of thousands of patients in the US are treated with intravascular stents creating an opportunity for both solutions. Although advancements such as drug eluting metal ste ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Novel carcinoma-specific monoclonal antibodies for therapies and diagnostics
SBC: Recodagen LLC Topic: 102Problems that cause significant negative impacts on cancer patientsandaposquality of life and on their survival include current therapies that lead to unwanted side effects due to their action on normal cellsFurthermoreinvading carcinoma cells can be resistant to therapies due to the migration proliferation dichotomyMonoclonal antibodyMabtherapiessuch as those against EGFVEGFc Met and their respec ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A novel immuno-oncolytic viral therapy for the treatment of non-small cell lung carcinoma
SBC: Western Oncolytics Ltd Topic: NCIProject Summary Abstract The goal of this project is to complete the pre clinical and translational studies necessary to prepare a novel oncolytic viralOVtherapyWO Sfor clinical evaluation in non small cell lung cancerNSCLCNSCLC is the predominate form of lung cancerwhich is the leading cause of cancer death in the United StatesRecentlyimmunotherapies have emerged as a potential new treatment appr ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia
SBC: Haima Therapeutics LLC Topic: NHLBIPROJECT SUMMARY ABSTRACT The normal platelet count in human blood isLand these platelets are responsible for efficient hemostatic surveillance and bleeding mitigation in the bodyThrombocytopeniaTCPlow platelet countis a condition caused by a decrease in platelet productionincrease in platelet destruction or consumptionor increase in splenic sequestrationThe age adjusted prevalence of immune thromb ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Accelerating Site-specific Characterization of Protein Therapeutics with Novel Machine Learning Methods
SBC: MASSMATRIX INC Topic: 400PROJECT SUMMARYABSTRACT TitleAccelerating Site specific Characterization of Protein Therapeutics with Novel Machine Learning Methods The project seeks to improve reliability and speed up the development of life saving and life enhancingprecisionprotein therapeutics and magnify the positive impact of biomedical research and education worldwideleading to a quantum leap in our understanding of the mo ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health